Genomic Testing for Improved Treatments in Breast Cancer

Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.